Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

被引：0

作者：

Gonzalez, Carmen ^{[1
]}

Simoes, Catia ^{[1
]}

Burgos, Leire ^{[1
]}

Martinez-Cuadron, David ^{[2
]}

Sarvide, Sarai ^{[1
]}

Alignani, Diego ^{[1
]}

Lopez, Aitziber ^{[1
]}

Gui, Yujuan ^{[3
]}

Komic, Hana ^{[4
]}

Schmachtel, Tessa ^{[5
]}

Botella, Carmen ^{[6
]}

Boyero, Raimundo Garcia ^{[7
]}

Santaolla, Esther Perez ^{[8
]}

Gil, Cristina ^{[9
]}

Algarra, Jesus Lorenzo ^{[10
]}

Lloris, Maria Jose Sayas ^{[11
]}

Ibanez, Francisco ^{[12
]}

Torres, Laura ^{[13
]}

Cano-Ferri, Isabel

Acuna-Cruz, Evelyn ^{[13
]}

Arce, Olga ^{[14
]}

Thoren, Fredrik B. ^{[4
]}

Rieger, Michael A. ^{[5
]}

San-Miguel, Jesus F. ^{[1
]}

Prosper, Felipe ^{[1
]}

Montesinos, Pau ^{[2
]}

Paiva, Bruno ^{[1
]}

机构：

[1] Univ Navarra, Ctr Invest Med Aplicada, CCUN, IDISNA,CIBER ONC,Clin Univ Navarra, Pamplona, Spain

[2] Hosp Univ & Politecn La Fe, Dept Hematol, Valencia, Spain

[3] BD Biosci, Single Cell Multi, Vianen, Netherlands

[4] Univ Gothenburg, Inst Biomed, TIMM Lab, Sahlgrenska Ctr Canc Res, Gothenburg, Sweden

[5] Goethe Univ Frankfurt, Dept Med Hematol Oncol 2, Frankfurt, Germany

[6] Hosp Gen Univ Alicante, Dept Hematol, Alicante, Spain

[7] Hosp Gen Univ Castellon, Castellon de La Plana, Spain

[8] Mendaro Hosp, Donostia San Sebastian, Spain

[9] Hosp Gen Univ Alicante, Alicante, Spain

[10] Hosp Gen Albacete, Albacete, Spain

[11] Hosp Dr Peset, Valencia, Spain

[12] Hosp Gen Univ Valencia, Valencia, Spain

[13] Hosp Univ & Politecn La Fe, Valencia, Spain

[14] Hosp Univ Basurto, Bilbao, Spain

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-203076

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4328 / 4329

页数：2

共 50 条

[21] Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry
Tettero, Jesse M.
Dakappagari, Naveen
Heidinga, Maaike E.
Oussoren-Brockhoff, Yvonne
Hanekamp, Diana
Pahuja, Anil
Burns, Kerri
Kaur, Pavinder
Alfonso, Zeni
van Der Velden, Vincent H. J.
te Marvelde, Jeroen G.
Hobo, Willemijn
Slomp, Jennichjen
Bachas, Costa
Kelder, Angele
Nguyen, Kevin
Cloos, Jacqueline
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2023, 104 (06) : 426 - 439
[22] AN EFFICIENT AND SIMPLE MULTIPARAMETER FLOW CYTOMETRY PROTOCOL TO DETECT MINIMAL RESIDUAL DISEASE (MRD) FOR ACUTE MYELOID LEUKEMIA (AML)
Li, Ke
Wang, Hui
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 356 - 357
[23] Measurable Residual Disease Assessment by Flow Cytometry in T-Cell Acute Lymphoblastic Leukemia
Gajendra, Smeeta
Gupta, Ritu
Gupta, Sanjeev Kumar
Gupta, Leena
Rai, Sandeep
Singh, Saroj
Prajapati, Vijay Kumar
Bakhshi, Sameer
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S264 - S265
[24] Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia
Venditti, A
Maurillo, L
Buccisano, F
Tamburini, A
Del Poeta, G
Del Principe, MI
Panetta, P
Consalvo, MI
Mazzone, C
Tendas, A
Trawinska, M
Forte, V
Amadori, S
LEUKEMIA & LYMPHOMA, 2003, 44 (03) : 445 - 450
[25] Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
Roehnert, Maximilian A.
Kramer, Michael
Schadt, Jonas
Ensel, Philipp
Thiede, Christian
Krause, Stefan W.
Buecklein, Veit
Hoffmann, Joerg
Jaramillo, Sonia
Schlenk, Richard F.
Roellig, Christoph
Bornhaeuser, Martin
McCarthy, Nicholas
Freeman, Sylvie
Oelschlaegel, Uta
von Bonin, Malte
LEUKEMIA, 2022, 36 (09) : 2208 - 2217
[26] Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
Maximilian A. Röhnert
Michael Kramer
Jonas Schadt
Philipp Ensel
Christian Thiede
Stefan W. Krause
Veit Bücklein
Jörg Hoffmann
Sonia Jaramillo
Richard F. Schlenk
Christoph Röllig
Martin Bornhäuser
Nicholas McCarthy
Sylvie Freeman
Uta Oelschlägel
Malte von Bonin
Leukemia, 2022, 36 : 2208 - 2217
[27] Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up
Rohnert, Maximilian Alexander A.
von Bonin, Malte
Kramer, Michael
Ensel, Philipp
Holtschke, Nadja
Rollig, Christoph
Bornhauser, Martin
Buecklein, Veit
Subklewe, Marion
Krause, Stefan W.
Voelkl, Simon
Berg, Tobias
Rieger, Michael A.
Brendel, Cornelia
Hoffmann, Jorg
Hofmeister-Mielke, Nicole
Schlenk, Richard F.
Freeman, Sylvie D.
Oelschlagel, Uta
BLOOD, 2020, 136
[28] Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
Gunaratne, Ruwan
Zhou, Crystal
Tai, Jesse W.
Schwede, Matthew
Tanaka, Kailee
Alkaitis, Matthew
Yin, Raymond
Sworder, Brian J.
Mannis, Gabriel
Majeti, Ravindra
Khodadoust, Michael S.
Kurtz, David M.
Zhang, Tian Y.
BLOOD, 2023, 142
[29] Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM study group
Langebrake, Claudia
Creutzig, Ursula
Dworzak, Michael
Hrusak, Ondrej
Mejstrikova, Ester
Griesinger, Frank
Zimmermann, Martin
Reinhardt, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) : 3686 - 3692
[30] Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts)
Sardesai, Sagar D.
Tan, Wei
Ford, Laurie Ann
Deeb, George
Block, Anne Marie W.
Sait, Sheila N. J.
McCarthy, Philip L.
Vigil, Carlos E.
Griffiths, Elizabeth A.
Thompson, James E.
Wang, Eunice S.
Wallace, Paul K.
Wetzler, Meir
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →